Fungi · Scientific monograph
Psilocybe cubensis
Magic Mushroom / Psilocybin Mushroom
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Psychiatric Research, Neurological & Cognitive Research, Substance Dependence Research
Research overview
Historical use
Used in Mesoamerican indigenous ceremonial and religious contexts for thousands of years, particularly by the Mazatec people of Oaxaca, Mexico (known as 'teonanácatl' — 'flesh of the gods'). Psilocybin was first isolated and synthesised by Albert Hofmann at Sandoz in 1958. Studied in the 1960s before being classified as Schedule I in the US in 1970, halting research for decades.
Modern research context
Psilocybin (the prodrug) and psilocin (the active metabolite) are the subject of renewed rigorous clinical research. A landmark N Engl J Med RCT demonstrated psilocybin to be non-inferior to escitalopram for depression [1]. A JAMA Psychiatry RCT demonstrated significant, durable antidepressant effects with two-dose psilocybin-assisted therapy for major depressive disorder [2]. A JAMA RCT confirmed single-dose efficacy for major depressive disorder [3]. A randomised controlled trial demonstrated significant response in treatment-resistant depression [4]. A meta-analysis confirmed consistent antidepressant effects across multiple RCTs [5]. FDA Breakthrough Therapy Designation has been granted for treatment-resistant depression and MDD.
Adverse effects
Acute (dose-dependent): perceptual distortions, synesthesia, ego dissolution, anxiety, confusion, tachycardia, hypertension, nausea. Challenging psychological experiences ('bad trips') — risk mitigated by psychological support/set-and-setting. Headache post-session. Hallucinogen persisting perception disorder (HPPD) — rare. No physical withdrawal syndrome. Non-addictive.
Contraindications
Personal or family history of schizophrenia, bipolar I disorder, or other psychotic disorders — absolute contraindication (risk of precipitating psychosis). Concurrent lithium — risk of seizures and hyperthermia (documented case reports). MAOIs — risk of serotonin syndrome. Uncontrolled cardiovascular disease — relative contraindication (transient hypertension/tachycardia).
Clinical and phytochemical data
Used part
Fruiting body (as pharmacological source); isolated psilocybin used in clinical trials
Primary active compounds
Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine — prodrug)
Psilocin (4-hydroxy-N,N-dimethyltryptamine — active metabolite)
Baeocystin
Norbaeocystin
Mechanism of action
Psilocybin is rapidly dephosphorylated to psilocin by alkaline phosphatase. Psilocin is a full agonist at serotonin 5-HT2A receptor in cortical pyramidal neurons, disrupting default mode network (DMN) activity. Also agonist at 5-HT2C and 5-HT1A. Promotes neuroplasticity via BDNF upregulation and synaptogenesis. AMPA/NMDA receptor modulation contributes to sustained antidepressant effect.
Pharmacokinetics
Absorption
Well-characterised in humans across multiple clinical studies. Psilocybin is a prodrug; it is rapidly dephosphorylated to the active metabolite psilocin by alkaline phosphatase in the intestinal mucosa, liver, and plasma within minutes of ingestion. Psilocin reaches peak plasma concentrations (Tmax) approximately 80–105 minutes after oral administration [1][2]. Oral bioavailability of psilocin from oral psilocybin is approximately 52–77% [2][4]. Food has minimal effect on absorption rate but may delay Tmax slightly.
Distribution
Psilocin is widely distributed throughout the body and readily crosses the blood-brain barrier, consistent with its central psychoactive effects. Plasma protein binding is approximately 50%. The volume of distribution is large (Vd ~1.2–1.4 L/kg), reflecting extensive tissue penetration [1][2]. CNS distribution to cortical 5-HT2A receptors is the pharmacologically relevant compartment.
Metabolism
Psilocybin is rapidly converted to psilocin (active form) via alkaline phosphatase-mediated dephosphorylation. Psilocin is subsequently metabolised via two primary pathways: (1) monoamine oxidase (MAO)-mediated oxidative deamination to 4-hydroxyindole-3-acetic acid (4-HIAA), and (2) UGT1A10-mediated glucuronidation to psilocin-O-glucuronide [3]. Minor metabolites include 4-hydroxytryptophol and norpsilocin. Significant interindividual variability in metabolic rate has been documented across clinical studies [3][4].
Excretion
Primarily renal. Approximately 15–20% of the administered psilocybin dose is recovered in urine as unchanged psilocin; the remainder is excreted as glucuronide conjugates and 4-HIAA [3][4]. The terminal elimination half-life of psilocin is approximately 2–3 hours [1][2]. Excretion is essentially complete within 24 hours, with no evidence of accumulation.
Safety and interactions
Drug interactions
Lithium carbonate — risk of seizures and hyperthermia (case reports of life-threatening interactions). MAOIs — significantly prolong and intensify effects; risk of serotonin syndrome. SSRIs — blunt acute psychedelic effects (5-HT2A downregulation); not thought to be dangerous but may reduce efficacy. Tramadol — serotonin syndrome risk.
Toxicity
Physiological toxicity very low: LD50 estimated at 280 mg/kg (oral, rats) — far above any human dose. No organ toxicity documented. Psychological risk (acute anxiety, rare HPPD) is the dominant clinical risk. Psilocybin is physiologically non-addictive and produces rapid tolerance; formal long-term safety data are limited to early-phase clinical research.
Special precautions
Pregnancy
No human data. Avoid in pregnancy. Animal studies show no teratogenicity at sub-psychedelic doses, but clinical use in pregnant individuals is contraindicated.
Lactation
No human data on breast milk excretion. Contraindicated during breastfeeding.
Hepatic impairment
Hepatic glucuronidation is the primary metabolic pathway; significant hepatic impairment may increase psilocin exposure. No clinical dose-adjustment data available.
Renal impairment
Primary excretion is renal; renal impairment may prolong psilocin exposure. No clinical dose-adjustment data. Monitor carefully.
Sources and references
- [1] - Carhart-Harris R., "Trial of Psilocybin versus Escitalopram for Depression.", N Engl J Med, 2021, PMID: 33852780
- [2] - Davis AK., "Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.", JAMA Psychiatry, 2021, PMID: 33146667
- [3] - Raison CL., "Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.", JAMA, 2023, PMID: 37651119
- [4] - Rosenblat JD., "Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial.", Med, 2024, PMID: 38359838
- [5] - Haikazian S., "Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.", Psychiatry Res, 2023, PMID: 37844352